Collaborations Between Biotech And Pharmaceutical Companies: New Agreements, April 29-June 8, 2005#
Biotech Co.* | Pharma Co. | Type/Product Area | Terms/Details (Date) |
AbGenomics | Boehringer Ingelheim International GmbH (Germany) | BI got worldwide rights to AbGenomics' antibody 168, which is targeted to a range of immune-related diseases | AbGenomics kept an option to co- promote resulting products in certain Asian countries; terms of the deal were not disclosed (6/6) |
Alimentary | Mead Johnson | Research and cross-licensing deal covering nutritional applications of novel ingredient technologies for infants and children | Each will contribute intellectual property to the research, and they will jointly fund development programs (4/28)@ |
Alliance | Beijing | They finalized a deal covering the development and sales of Alliance's Oxygent in China | Alliance will get up-front fees and is eligible |
Anadys | Novartis Pharma AG (Switzerland) | Exclusive deal to develop ANA975 and additional Toll-like receptor 7 oral prodrugs for hepatitis B and C and possibly other infectious diseases | Anadys gets an initial license payment of $20M and up to $550 million in regulatory and commercial milestone payments; Anadys also has an option to retain 35% of profits in the U.S. by contributing 35% of costs; otherwise it would get royalties on any resulting sales (6/2) |
BioMarin | Daiichi Suntory Pharma Co. Ltd. (Japan) | BioMarin licensed tetrahydro-biopterin (6R-BH4) to treat the endothelial dysfunction that causes vascular complications in various diseases | BioMarin previously licensed rights to the drug for use in genetic diseases, including phenylketonuria; Daiichi gets an up-front payment, development milestones for up to two indications, and royalties on any sales (5/5) |
BioXell SpA* | Merck & Co. Inc. | Merck got exclusive rights to develop TREM-related therapeutic and diagnostic products; TREM is Triggering Receptors Expressed on Myeloid Cells | BioXell gets an up-front payment and up to $150M in milestone payments, including $55.5M for successful development of the first product for the first indication; it also would get royalties on any sales (5/23) |
Cangen | Olympus Corp. (Japan) | Deal to develop a hybrid DNA- based and protein-based diagnostic test for lung cancer | Cangen gets access to Olympus' microarray technology in the deal, terms of which were not disclosed (5/25) |
Cellzome Inc.* | Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) | Ortho exercised its option to develop Cellzome's Gamma Secretase Modulator program | The license stems from a March 2005 deal in Alzheimer's disease; Cellzome gets an additional technology access fee and continued research funding, as well as potential milestone and royalty payments (5/23) |
Cerus Corp. | BioOne Corp. (Japan) | Definitive agreement calls for BioOne to commercialize the Intercept Blood System for plasma in much of Asia | Cerus already received $3M when a letter of intent was signed in January; potential up-front and milestone payments total $33M in cash and BioOne equity; Cerus also would get royalties on sales in the covered countries (6/6) |
Chromos | Pfizer Inc. | Pfizer got rights to use the ACE System to develop cell lines for research, development and manufacturing purposes | The deal represents an expansion of a December 2004 deal under which Chromos is using the system to engineer cell lines to express a Pfizer protein; terms were not disclosed (5/30) |
Codexis Inc.* | Bristol-Myers Squibb Co. | Deal to improve biocatalyst productivity for an undisclosed product candidate from BMS | Codexis gets research funding and a potential milestone payment; BMS may opt at that point to fund further research, which involves Codexis' re-engineering platform (5/24) |
ComGenex | Fournier Pharma (France) | Collaboration under which ComGenex will provide exclusive chemistry services to Fournier for three years | Fournier extended an initial 16-month project into the multiyear collaboration, terms of which were not disclosed (5/17) |
Compugen | Ortho-Clinical Diagnostics Inc. (unit of Johnson & Johnson) | Deal to develop diagnostic products based on biomarkers discovered by Compugen; Ortho initially can develop up to nine biomarkers | Ortho gets worldwide rights to resulting products; Compugen is entitled to license fees and milestone payments for each biomarker, as well as royalties on any sales (6/8) |
Cornerstone | Lupin Ltd. (India) | Collaboration to develop a drug delivery system for an anti-infective product | Lupin gets up to $10.5M in milestone and other payments, and royalties on any sales; Cornerstone has marketing rights in the U.S. (5/9) |
Crucell NV | Ferring Pharmaceuticals A/S (Denmark) | Ferring got rights to use the PER.C6 cell line in the field of women's health care | The deal includes Crucell's allied contract manufacturer DSM Biologics; terms were not disclosed (5/25) |
Cyntellect | Sigma-Aldrich Corp. | Sigma-Aldrich got exclusive, worldwide rights to commercialize Cyntellect's Cell Xpress service | Cyntellect got a multimillion-dollar equity investment, and will get royalties on sales; Sigma-Aldrich also will pay for internal use of Cyntellect's LEAP technology (4/27)@ |
Cytogen Corp. | The Dow Chemical Co. | Cytogen and Dowpharma are collaborating to create a targeted product for treating prostate and other cancers | Dow technology will be used to radiolabel Cytogen's PSMA antibody (7E11); the deal extends an existing agreement; terms were not disclosed (5/10) |
Diatos SA* | Servier (France) | Deal to apply Diatos' Vectocell technology to a small-molecule cancer candidate from Servier | Servier will fund work at Diatos, and gets an option to license resulting technology (5/17) |
EraGen | Bayer HealthCare LLC | Bayer Diagnostics got exclusive rights to Eragen's MultiCode-PLx System for use in cystic fibrosis | Bayer also got rights to a create assays for other disease states; MultiCode-PLx is a high-throughput genotyping system; terms of the deal were not disclosed (5/18) |
ExonHit | Allergan Inc. | They extended deal from 2003 to develop drugs for neurodegenerative diseases, pain and ophthalmology | ExonHit got a $2M payment and continues to receive R&D support; it also is entitled to milestone and royalty payments, and has certain co-development and co- commercialization options (5/17) |
454 Life | F. Hoffmann-La Roche Ltd. (Switzerland) | Exclusive five-year deal for sales and distribution of 454's nanotechnology- based genome-sequencing systems | 454 will get up to $62M in license fees, milestones related to instrument releases, minimum royalties and research funding; it also would get royalties on sales (5/12) |
Fulcrum | Syngenta Biopharma (Switzerland) | Fulcrum will provide development services for Syngenta | The focus is on advancing Syngenta projects toward clinical development; terms of the deal were not disclosed (5/18) |
GeneGo Inc.* | Procter & Gamble Pharmaceuticals Inc. | P&G licensed MetaCore and MetaBase technologies from GeneGo | The products are used in life science research; terms of the deal were not disclosed (5/9) |
Haptogen | DaeWoong Pharmaceutical Co. Ltd. (South Korea) | Collaboration to progress the clinical development of antibody therapeutics targeted to bacterial infections | They will combine Haptogen's discovery approach with the formulation, manufacturing and marketing expertise of DaeWoong; terms were not disclosed (5/17) |
Hybridon | Novartis Pharma AG (Switzerland) | Collaboration to discover and develop Toll-like receptor 9 drugs targeting asthma and allergy | First they will evaluate immune modulatory oligonucleotide candidates; Hybridon then could earn up-front license fees along with milestone payments that could total $136M, as well as royalties on sales (6/1) |
Inovio | Merck & Co. Inc. | Merck exercised an option for a nonexclusive license to an additional antigen to be used with Inovio's MedPulser DNA Delivery System | Inovio gets an option fee and remains eligible for milestone and royalty payments; Merck now has licensed three antigens under their 2004 license agreement (5/12) |
Inpharmatica | Daiichi Pharmaceutical Co. Ltd. (Japan) | Daiichi licensed Inpharmatica's Admensa Interactive technology | The technology is a suite of predictive ADME models and compound-prioritization tools; terms were not disclosed (6/6) |
Intra-Cellular Therapies Inc.* | Bristol-Myers Squibb Co. | ITI got worldwide rights to a family of preclinical compounds targeting central nervous system diseases | BMS receives an undisclosed license fee up front, and potential milestone and royalty payments (6/1) |
Isis | Pfizer Inc. | Deal to identify second- generation antisense drugs for treating ophthalmic disease | Isis gets a $1M technology access fee and research funding, and is eligible to receive milestone and royalty payments (5/24) |
Kiadis BV* | NV Organon (the Netherlands; unit of Akzo Nobel) | Deal to evaluate Kiadis' BioSelect screening technology in Organon's reproductive medicine discovery program | Kiadis intends to deliver novel active compounds against the target provided by Organon; terms of the deal were not disclosed (5/25) |
Large Scale | Bayer | Collaboration to investigate the plant-based expression of LSBC's lysosomal acid lipase | The goal is to develop a therapeutic product; terms of the deal were not disclosed (4/29) |
Lexicon Genetics Inc. (LEXG) | NV Organon (the Netherlands; unit of Akzo Nobel) | Collaboration under which Lexicon will create and analyze mouse knockouts of 300 genes to identify drug targets | They will share R&D costs and any revenue; Lexicon gets $22.5M up front, and research funding of up to $50M a year during the four-year target-function discovery portion of the alliance (5/17) |
Macrocyclics Inc.* | MDS Nordion (Canada) | Deal to develop bifunctional chelates for use in molecular imaging and targeted therapeutics | Terms of the three-year deal were not disclosed (5/26) |
Medarex Inc. | Ono Pharmaceutical Co. Ltd. (Japan) | Collaboration to research and develop a fully human anti-PD-1 antibody for treating cancer | They will share costs through Phase II trials; then each would be responsible for its own territory; Medarex has rights in North America, Ono everywhere else (5/12) |
Metabolex | Astellas Pharma Inc. (Japan) | They extended for one year a 2002 deal to validate drug targets for the treatment of Type II diabetes and obesity | Metabolex gets research funding and mile- stone payments under the extension; it would receive royalties on any sales, and retained co-promotion rights in North and South America (5/2) |
Miikana | F. Hoffmann-La Roche Ltd. (Switzerland) | Miikana got worldwide rights to Roche's MKC-1, an anticancer agent in Phase II trials | Roche gets an equity stake in Miikana, as well as undisclosed up-front, milestone and royalty payments (5/3) |
Morphotek | GlaxoSmithKline plc (UK) | Morphotek will apply its Morphodome technology to GSK's antibody producer lines to develop cell lines with improved characteristics | Morphotek gets R&D funding for an initial project, which could lead to two more projects; Morphotek also could receive annual fees, and is eligible for milestone payments (5/18) |
Myogen Inc. | Novartis AG (Switzerland) | They expanded a deal from 2003 to include Myogen's histone deacetylase inhibitor program | The expansion extends research funding for at least three years and includes undisclosed signing fees, as well as milestone and royalty provisions; Myogen also has certain co-promotion and profit-sharing options (5/26) |
Neurologix | Medtronic Inc. | Deal to develop and market micro- infusion catheters to deliver gene therapy into the brain and central nervous system | Neurologix got a $2M equity investment in the deal; Medtronic is entitled to milestone payments, and they would share revenues from any resulting device (5/2) |
Odyssey | Pfizer Inc. | They expanded a deal to profile compounds across Odyssey's panel of cell-based assays | The project will focus on 500 compounds from multiple therapeutic areas; terms of the deal were not disclosed (5/17) |
Optimer | Par Pharmaceutical Co. Inc. | Collaboration on a narrow- spectrum antibiotic (now named PAR-101) active against Clostridium difficile; it is in Phase II trials | Par acquired a 16% partnership interest in Optimer; Optimer will fund development; Par would pay royalties on sales, and has an option to develop three other Optimer compounds (5/3) |
Oxford | Pfizer Inc. | Pfizer got rights to use the LentiVector gene delivery system for research activities | Oxford BioMedica gets an up-front license payment and annual maintenance fees; further terms were not disclosed (6/6) |
Portola | Astellas Pharma Inc. (Japan) | Collaboration to advance the development of a series of Astellas preclinical compounds | Portola scientists have identified the anti- thrombotic properties of the compounds; terms of the deal were not disclosed (6/6) |
Prosidion Ltd. | Undisclosed company | The unnamed firm got non- exclusive rights to use DPIV inhibitors for Type II diabetes and related conditions | The agreement covering dipeptidyl peptidase IV inhibitors includes undisclosed upfront, milestone and royalty payments to Prosidion (5/12) |
Proteologics | Teva Pharmaceuticals Industries Ltd. (Israel) | Deal to study the feasibility of using drugs targeting ubiquitin ligases for cancer therapy | Teva made an equity investment as part of the deal, and has an option to license the program; if so, Proteologics would be enti- tled to milestone and royalty payments (5/3) |
Protez | Sumitomo Pharmaceuticals Co. Ltd. (Japan) | Deal to develop and commercialize SMP-601, Sumitomo's injectable antibiotic, in North America and Europe | Protez will provide development and commercialization milestones, as well as royalties on any sales; its license is exclusive in NorthAmerica and Europe (5/17) |
Renovis Inc. | Pfizer Inc. | Worldwide deal to develop small molecules that target the vanilloid receptor, VR1, for treating pain, urinary incontinence and other conditions | They will combine their current VR1 R&D programs; Renovis gets a $10M license fee and more than $7M in research funding over two years; Renovis also can earn $170M in milestone payments for each resulting product, as well as royalties on sales (5/31) |
Response | Roche Diagnostics (Switzerland) and Eli Lilly and Co. | Deal to confirm biomarkers for use to identify patients most likely to respond to certain cancer therapies | Roche and Lilly entered a collaboration initially focused on Lilly's Alimta and Gemzar; they will work with Response Genetics on biomarker tests (5/11) |
Sinovac | LG Life Sciences Ltd. (South Korea) | They agreed to collaborate on marketing efforts and vaccine supply for China and international markets | They will work on international marketing of Sinovac's Healive hepatitis A vaccine; Sinovac will introduce LG's HepB vaccines into China; and they jointly will work on Sinovac's influenza vaccine (Anflu); terms of the deal were not disclosed (5/18) |
Valentis Inc. | Schering AG (Germany) | Expanded deal gives Schering nonexclusive rights to use GeneSwitch and PINC technologies in its research | Valentis gets up-front license fee and is entitled to yearly maintenance fees; an earlier deal gave Schering rights to the technologies for use with two genes (6/7) |
Valentis Inc. | Organon Laboratories Ltd. (UK) | Organon licensed rights to use Valentis' GeneSwitch gene-regulation technology for research purposes | Valentis got a license fee and is entitled to yearly license maintenance fees; further terms of the nonexclusive license were not disclosed (5/25) |
Vical Inc. | Merck & Co. Inc. | Merck exercised three options under an existing deal, giving it rights to use Vical's nonviral gene delivery technology in cancer vaccine applications | Vical gets a $3M payment and it entitled to milestone and royalty payments; Vical also has certain co-promotion rights for resulting products (6/8) |
XenoTech | Bristol-Myers Squibb Co. | Three-year deal under which BMG got rights to immortalized Fa2N-4 hepatocytes for internal testing purposes | Terms were not disclosed; XenoTech is licensee of the technology from MultiCell Technologies Inc. (5/23) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
@ News occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||